FDA warns against using compounded semaglutide
The FDA has received adverse event reports after patients used compounded semaglutide for type 2 diabetes and weight loss. Drug...


FDA warns against using compounded semaglutide
AOMs help patients manage postsurgical weight recurrence
AOMs help patients manage postsurgical weight recurrence
Obesity will become the most important risk factor for heart attacks
FDA warns against using compounded semaglutide
Journal Watch 31/05/2023
Obesity increases risk of mental disorders
Researchers design strategy to fight obesity through gene therapy
Body contouring does not offer clinically significant, long-term sustained weight loss benefit
Olympus launches POWERSEAL Sealer/Divider, a next level surgical bipolar energy device in EMEA
Journal watch 24/05/2023
B cells promote liver cancer with dangerous dual strategy
Endotoxin fragments help drive obesity
OASIS 1 trial: Oral semaglutide 50mg achieves 15.1% weight loss